YARTEMLEA
LaunchmAbnarsoplimab
BLAINTRAVENOUSINJECTIONPriority Review
Approved
Dec 2025
Lifecycle
Launch
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 9h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
YARTEMLEA (narsoplimab) is a monoclonal antibody approved for intravenous administration in December 2025. The specific indications and mechanism of action require clinical validation post-launch. This is a newly approved biologic entering the market in active launch phase.
Growth
Early-stage launch product with moderate competitive pressure (30) suggests growing team investment and expansion opportunities for commercial and medical affairs roles.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
This newly launched IV biologic represents a foundational opportunity for professionals joining a product in active growth phase with no linked jobs currently posted. Early involvement in market establishment, label expansion, and competitive positioning offers meaningful career development and influence on product trajectory.
Brand ManagerSenior Brand Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.